Daniel Levine is a Co-Founder at CellType, a Y Combinator-backed agentic drug discovery company building AI agents and biological foundation models that simulate human biology to accelerate drug development.
He earned his Ph.D. in Mathematics from Penn State University, specializing in algebraic geometry, before transitioning into machine learning and joining Yale University as a Postdoctoral Researcher in the van Dijk Lab.
Daniel is a lead author of Cell2Sentence (C2S), a groundbreaking method published at ICML 2024 that teaches large language models the language of biology by encoding single-cell gene expression as text, co-developed in collaboration with Google DeepMind.
CellType is a Y Combinator W26 company already working with Top 10 pharmaceutical companies, with its core technology having discovered and validated a novel cancer treatment signal.
The C2S-Scale model scales to 27 billion parameters trained on over one billion transcriptomic tokens, achieving state-of-the-art performance on single-cell biology tasks.
other founders
